IFNB1 and renal carcinoma: The marked differences between in vitro and in vivo effects of type I IFNs were further corroborated by a study showing that monocytes from patients with untreated renal carcinoma exerted increased monocyte antibody-dependent cellular cytotoxicity (ADCC) after in vitro IFN-β treatment, while monocytes isolated 4 hours after IFN-β treatment of patients displayed decreased ADCC activity (150).